Hi-TIDe : LAbCore immunoglobulin discovery and engineering


Our focus

Using proprietary platform capabilities, our mission is the de novo discovery and development (research-to-GMP) of immunoglobulins of high potential therapeutic interest that can be exploited for the clinical targeting of solid tumors and cancer-related disease processes.


Our projects

  • We are developing approaches for the efficient and effective isolation and optimization of fully human ‘warhead’ binder molecules using phage-display library technology. We constantly ask how best to design and construct such libraries and to subsequently select, screen and rank binders for downstream applications.
  • In addition to fully in vitro discovery, we ask whether native immunoglobulins produced by tumor infiltrating B cells represent good starting points for the development of functional anti-tumor molecules.
  • We have established a pipeline of novel CAR/BiTE-compatible molecules for downstream experimental evaluation and clinical translation.
  • We are investigating the utility of  an engineered non-TCR immunoglobulin scaffold for the stringent and selective targeting of therapeutically disease-relevant pMHC complexes In parallel, we are using proprietary in vitro display technology to investigate the physical basis of TCR:pMHC recognition and to explore how we might best mitigate the potential for undesirable cross-reactivity of pMHC targeting agents.
  • We support the advancement of existing global LCR therapeutic monoclonal antibody candidates by conducting directed optimization and humanization studies. Current examples are two potential ‘best-in-class’ humanized anti-TGFb mAbs with exquisite selectivity for discrete TGFb isoforms.
  • We have established a significant program for the discovery and collaborative development of novel TEM1-targeting antibodies and their fragments. These are being evaluated in T cell redirection studies as BiTETMs and CARS, and also for their potential suitability in nuclear medicine and tumor imaging.



UNIL web teasers general.png


News @ Dunn Lab

New approach for the immunotherapeutic targeting of TEM1+ tumors

New approach for the immunotherapeutic targeting of TEM1+ tumors

Follow us:  


Lausanne Oncology DUNN lab.png

Steven DUNN
Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Ludwig Lausanne RGB-crop461x374.jpg (Print)

Phone +41 21 692 59 51
Fax +41 21 692 59 95 



WEB medallions 150 x100-1.png

Featured publication -------

VIGNETTE web (1).png

Soluble trivalent engagers redirect cytolytic T cell activity towards tumor endothelial marker 1 (TEM1)
Jul-2021 | ...Steven Dunn

Ch. des Boveresses 155 - CH-1066 Epalinges
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer ResearchUniversité de LausanneCentre Hospitalier Universitaire Vaudois (CHUV)